ReviewMusculoskeletal surgery2026
Transcatheter arterial microembolization (TAME) in foot and ankle pathologies: current indications and future perspectives.
Review in Musculoskeletal surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transcatheter arterial microembolization (TAME) is a minimally invasive endovascular procedure initially developed for bleeding control and later applied to the treatment of chronic musculoskeletal conditions characterized by pathological hypervascularization, to inhibit or reduce the release of inflammatory mediators. First introduced in anatomical districts such as the knee, TAME has more recently been proposed as a therapeutic option for chronic inflammatory foot and ankle disorders refractory to conservative treatment. A narrative review of the literature was conducted by searching PubMed using the keywords "microembolization," "transcatheter arterial microembolization," "TAME," "foot," and "ankle." The most recent and relevant studies, including case reports, case series, and retrospective studies, were analyzed, along with the reference lists of selected articles. Clinical indications, procedural techniques, embolic materials, clinical outcomes, and complications were evaluated. The main indications for TAME in foot and ankle pathology were Achilles tendinopathy, plantar fasciopathy, and, in a single reported case, non-union of a fifth metatarsal fracture. The procedure was predominantly performed using temporary embolic agents, most commonly imipenem/cilastatin sodium. All studies reported a technical success rate of 100%, with significant pain reduction and functional improvement in most patients. Reported complications were minor and transient, with no major adverse events documented.TAME represents a promising minimally invasive therapeutic option for chronic inflammatory foot and ankle conditions refractory to conservative management, particularly Achilles tendinopathy and plantar fasciopathy. Although preliminary clinical results are encouraging, the current evidence is limited by small sample sizes and low methodological quality, underscoring the need for larger, well-designed prospective studies.
Indexed as
Identifiers
41973173What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.